New targeted pill for advanced HR+/HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an experimental pill that targets a protein called Aurora A kinase, which may help overcome resistance to standard treatments. The goal is to see if adding this pill to your usual hormone and HER2 therapy can slow down or stop the growth of your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have breast cancer that has spread to other parts of the body (metastatic) and is both HR+ and HER2+.
- You have already had at least 4 cycles of standard first treatment (chemotherapy with targeted drugs like trastuzumab and pertuzumab, or T-DXd) and your cancer did not grow during that time.
- You are starting or continuing hormone therapy and HER2-targeted treatment.
- Your heart function is at least 50% (confirmed by a recent echo or MUGA scan), and your organ function is adequate.
- You are willing to receive growth factor injections to prevent low white blood cell counts on this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
This trial tests an experimental pill (TR115) in people whose tumors have a specific gene change (ARID1A mutation). The drug aims to stop cancer growth by blocking a protein involved in cell division, and the study hopes to find out if it works against different types of advanced cancer, including ovarian and endometrial cancer.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.